The potential for achieving a high proportion of pathologic complete responses with neoadjuvant therapy in muscle-invasive bladder cancer has raised the possibility of a paradigm-shifting approach of curative-intent bladder-sparing therapy alone in a subset of this patient population.
According to the results of the global phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan is the optimal second-line treatment option for patients with HER2-positive metastatic gastric…
Belantamab mafodotin, an antibody-drug conjugate targeting BCMA in multiple myeloma, is likely to regain FDA approval based on the DREAMM-7 and DREAMM-8 trials. In this…
Abstract. Introduction: Many patients have residual disease after neoadjuvant therapy but their prognosis and need for adjuvant therapy is unclear. This study evaluates patient prognosis…
Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss practical applications of AI in the clinical workflow as well as its potential to improve patient-centered care,…
Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss practical applications of AI in the clinical workflow as well as its potential to improve patient-centered care,…
Updates from the monarchE and NATALEE trials have reshaped the therapeutic landscape for patients with ER-positive, HER2-negative early-stage breast cancer, giving CDK4/6 inhibitors a prominent…
The role of radical cystectomy in the era of enfortumab vedotin plus pembrolizumab (EVP) must be individualized, based on the patient’s response to EVP treatment,…
Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic…
Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as…
